Novel therapeutic approaches for cutaneous T cell lymphomas

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785..
   PubMed Web of Science ®Google Scholar
• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714.
   PubMed Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer. 2017;77:57–74.
   PubMed Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–1722.
   PubMed Web of Science ®Google Scholar
• Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005;32(10):647–674.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, et al. Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771.
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised international society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739.
   PubMed Web of Science ®Google Scholar
• Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res. 2002;160:271–280.
   PubMedGoogle Scholar
• Fujii K. New therapies and immunological findings in cutaneous T-cell lymphoma. Front Oncol. 2018;8:198.
   PubMed Web of Science ®Google Scholar
• Nashan D, Faulhaber D, Ständer S, et al. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007;156(1):1–10.
   PubMed Web of Science ®Google Scholar
• Iyer A, Hennessey D, O’Keefe S, et al. Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing. Blood Advances. 2019;3(7):1175–1184.
   PubMed Web of Science ®Google Scholar
• Edinger JT, Clark BZ, Pucevich BE, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides. Am J Surg Pathol. 2009;33(12):1860–1868.
   PubMed Web of Science ®Google Scholar
• Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112(8):3082–3087..
   PubMed Web of Science ®Google Scholar
• Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643–1649.
   PubMed Web of Science ®Google Scholar
• Talpur R, Sui D, Gangar P, et al. Retrospective analysis of prognostic factors in 187 cases of transformed Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016;16(1):49–56.
   PubMed Web of Science ®Google Scholar
• Pulitzer M. Cutaneous T-cell Lymphoma. Clin Lab Med. 2017;37(3):527–546.
   PubMed Web of Science ®Google Scholar
• Bosisio FM, Cerroni L. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas. Am J Dermatopathol. 2015;37(2):115–121.
   PubMed Web of Science ®Google Scholar
• Salgado R, Servitje O, Gallardo F, et al. Oligonucleotide array-cgh identifies genomic subgroups and prognostic markers for tumor stage mycosis fungoides. J Invest Dermatol. 2010;130(4):1126–1135.
   PubMed Web of Science ®Google Scholar
• Papadaki M, Saraki K, Karagianni F, et al. Cutaneous T-cell lymphoma: aetiopathogenesis and current diagnostic and therapeutic developments. Eur J Dermatol. 2020;30(2):85–102.
   Web of Science ®Google Scholar
• Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas. J Am Acad Dermatol. 2002;46(1):95–106.
   PubMed Web of Science ®Google Scholar
• Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol. 2010;130(6):1707–1718.
   PubMed Web of Science ®Google Scholar
• Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2003;148(4):709–718.
   PubMed Web of Science ®Google Scholar
• Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19(14):3755–3763.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood. 2009;114(14):2936–2944.
   PubMed Web of Science ®Google Scholar
• Saulite I, Hoetzenecker W, Weidinger S, et al. Sézary syndrome and atopic dermatitis: comparison of immunological aspects and targets. BioMed Res Int. 2016;2016:9717530.
   PubMed Web of Science ®Google Scholar
• Kallinich T, Muche JM, Qin S, et al. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol. 2003;121(5):1045–1052.
   PubMed Web of Science ®Google Scholar
• Sokolowska-Wojdylo M, Wenzel J, Gaffal E, et al. Circulating clonal CLA+ and CD4+ T cells in Sézary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol. 2005;152(2):258–264.
   PubMed Web of Science ®Google Scholar
• Kohnken R, Fabbro S, Hastings J, et al. Sézary syndrome: clinical and biological aspects. Curr Hematol Malig Rep. 2016;11(6):468–479.
   PubMed Web of Science ®Google Scholar
• Tumes DJ, Papadopoulos M, Endo Y, et al. Epigenetic regulation of T-helper cell differentiation, memory, and plasticity in allergic asthma. Immunol Rev. 2017;278(1):8–19.
   PubMed Web of Science ®Google Scholar
• Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 2005;105(4):1640–1647.
   PubMed Web of Science ®Google Scholar
• Gjerdrum LM, Woetmann A, Odum N, et al. FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia. 2007;21(12):2512–2518.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A. 2009;106(6):1903–1908.
   PubMed Web of Science ®Google Scholar
• Borcherding N, Voigt AP, Liu V, et al., Single-Cell profiling of cutaneous T-Cell lymphoma reveals underlying heterogeneity associated with disease progression. Clin Cancer Res. 2019;25(10): 2996–3005.
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Marinos L, Moustou E, et al. Psoriasis in patients with mycosis fungoides: a clinicopathological study of 25 patients. J Eur Acad Dermatol Venereol. 2017;31(11):1848–1852.
   PubMed Web of Science ®Google Scholar
• Yumeen S, Girardi M. Insights into the molecular and cellular underpinnings of cutaneous T cell lymphoma. Yale J Biol Med. 2020;93(1):111–121.
   PubMed Web of Science ®Google Scholar
• Juvekar A, Manna S, Ramaswami S, et al. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res. 2011;9(2):183–194.
   PubMed Web of Science ®Google Scholar
• Stutz N, Johnson RD, Wood GS. The Fas apoptotic pathway in cutaneous T-cell lymphomas: frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol. 2012;67(6):1327.e1–1327.e10.
   PubMed Web of Science ®Google Scholar
• Braun FK, Al-Yacoub N, Plötz M, et al. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol. 2012;132(2):429–439.
   PubMed Web of Science ®Google Scholar
• Ionescu MA, Rivet J, Daneshpouy M, et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52(1):32–39.
   PubMed Web of Science ®Google Scholar
• Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-Cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783–2785.
   PubMed Web of Science ®Google Scholar
• Chang DK, Sui J, Geng S, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther. 2012;11(11):2451–2461.
   PubMed Web of Science ®Google Scholar
• Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol. 2000;18(1):621–663.
   PubMed Web of Science ®Google Scholar
• Vaqué JP, Gómez-López G, Monsálvez V, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123(13):2034–2043.
   PubMed Web of Science ®Google Scholar
• Ungewickell A, Bhaduri A, Rios E, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056–1060..
   PubMed Web of Science ®Google Scholar
• Choi J, Goh G, Walradt T, et al., Genomic landscape of cutaneous T cell lymphoma. Nat Genet. 2015;47(9): 1011–1019.
   PubMed Web of Science ®Google Scholar
• Pérez C, Mondéjar R, García-Díaz N, et al., Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-κB and nuclear factor of activated T cells pathways. Br J Dermatol. 2020;182(1): 147–155.
   PubMed Web of Science ®Google Scholar
• Lin WM, Lewis JM, Filler RB, et al. Characterization of the DNA copy-number genome in the blood of cutaneous T-Cell lymphoma patients. J Invest Dermatol. 2012;132(1):188–197..
   PubMed Web of Science ®Google Scholar
• Levidou G, Siakantaris M, Papadaki T, et al. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. J Am Acad Dermatol. 2013;69(3):375–384.
   PubMed Web of Science ®Google Scholar
• Cristofoletti C, Bresin A, Picozza M, et al. Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance. Leukemia. 2019;33(5):1231–1242.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2017;28(10):2517–2525.
   PubMed Web of Science ®Google Scholar
• Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and Sézary syndrome. Dermatol Clin. 2015;33(4):807–818.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol. 2013;168(1):192–200.
   PubMed Web of Science ®Google Scholar
• Alpdogan O, Kartan S, Johnson W, et al. Systemic therapy of cutaneous T-cell lymphoma (CTCL). Chinese Clin Oncol. 2019;8(1):10.
   PubMedGoogle Scholar
• Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19(9):2456–2471.
   PubMed Web of Science ®Google Scholar
• Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol. 2000;1(5):307–314.
   PubMedGoogle Scholar
• Kapser C, Herzinger T, Ruzicka T, et al. Treatment of cutaneous T-cell lymphoma with oral alitretinoin. J Eur Acad Dermatol Venereol. 2015;29(4):783–788.
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Patsatsi A, Sidiropoulou P, et al. Monotherapy and combination therapy with acitretin for mycosis fungoides: results of a retrospective, multicentre study. J Eur Acad Dermatol Venereol. 2020;34(11):2534–2540.
   PubMed Web of Science ®Google Scholar
• Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085–1094.
   PubMed Web of Science ®Google Scholar
• Ni X, Jorgensen JL, Goswami M, et al. Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and sézary syndrome. Clin Cancer Res. 2015;21(2):274–285.
   PubMed Web of Science ®Google Scholar
• Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192–1204.
   PubMed Web of Science ®Google Scholar
• Van De Donk NWCJ, Dhimolea E. Brentuximab vedotin. MAbs. 2012;4(4):458–465.
   PubMed Web of Science ®Google Scholar
• Kung Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem. 2006;281(15):10540–10547.
   PubMed Web of Science ®Google Scholar
• Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22–27.
   PubMed Web of Science ®Google Scholar
• Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758.
   PubMed Web of Science ®Google Scholar
• Prince HM, Kim YH, Horwitz S, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555–566.
   PubMed Web of Science ®Google Scholar
• Papadavid E, Pappa V, Kapniari E, et al. Real life data on advanced cutaneous T cell lymphoma patients treated with brentuximab vedotin: results from a multicenter European EORTC study. Eur J Cancer. 2019;119:S34–S35.
   Web of Science ®Google Scholar
• Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19(2S):S27–S32.
   PubMedGoogle Scholar
• Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-Treated CTCL patients. Sci Transl Med. 2012;4(117):117ra7.
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood. 2003;101(11):4267–4272.
   PubMed Web of Science ®Google Scholar
• Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784–794.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Teague JE, Fisher DC, et al. Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission. JAMA Dermatol. 2014;150(7):776–779.
   PubMed Web of Science ®Google Scholar
• Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160–1170.
   PubMed Web of Science ®Google Scholar
• Battistella M, Leboeuf C, Ram-Wolff C, et al. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017;130(26):2900–2902.
   PubMed Web of Science ®Google Scholar
• Marie-Cardine A, Viaud N, Thonnart N, et al. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma. Cancer Res. 2014;74(21):6060–6070.
   PubMed Web of Science ®Google Scholar
• Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood. 2003;102(12):4059–4066.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Harrison DL, Song Y, et al. Antigen-Presenting cell-Intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells. Cell Rep. 2018;24(2):379–390.e6.
   PubMed Web of Science ®Google Scholar
• Gibson HM, Mishra A, Chan DV, et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for sézary syndrome. J Invest Dermatol. 2013;133(1):249–257.
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20–28.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Bergman R. Complete regression of mycosis fungoides after ipilimumab therapy for advanced melanoma. JAAD Case Rep. 2015;1(2):99–100.
   PubMedGoogle Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(8):1281–1283.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66(1):311–328.
   PubMedGoogle Scholar
• Groner B, Von Manstein V. Jak stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1–14.
   PubMed Web of Science ®Google Scholar
• Matutes E. The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms. Int J Lab Hematol. 2018;40:97–103.
   PubMed Web of Science ®Google Scholar
• Park J, Yang J, Wenzel AT, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood 2017;130(12):1430–1440.
   PubMed Web of Science ®Google Scholar
• Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib. Recent Results Cancer Res. 2018;212:119–132.
   PubMedGoogle Scholar
• Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75(11):2187–2199.
   PubMed Web of Science ®Google Scholar
• Curran SA, Shyer JA, St Angelo ET, et al. Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1/2 blockade. Cancer Immunol Res. 2017;5(1):52–60.
   PubMed Web of Science ®Google Scholar
• Karagianni F, Saraki K, Papadaki M, et al. In vitro effect of Jak and HDAC inhibitors in cutaneous T-cell lymphoma. Eur J Cancer. 2019;119:S4.
   Web of Science ®Google Scholar
• Waldmann TA. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: inspired by functional and structural genomics. Mol Cell Endocrinol. 2017;451:66–70.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243.
   PubMed Web of Science ®Google Scholar
• Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016;2016:1–15. [ 2016].
   Web of Science ®Google Scholar
• Schoepflin ZR, Shapiro IM, Risbud MV. Class i and IIa HDACs mediate HIF-1α stability through PHD2-dependent mechanism, while HDAC6, a class IIb member, promotes HIF-1α transcriptional activity in nucleus pulposus cells of the intervertebral disc. J Bone Miner Res. 2016;31(6):1287–1299.
   PubMed Web of Science ®Google Scholar
• Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene. 2002;21(3):427–436.
   PubMed Web of Science ®Google Scholar
• Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and n vivo. Mol Cancer Ther. 2008;7(4):759–768.
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Ali S, Pace PE, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001;7(4):971–976.
   PubMed Web of Science ®Google Scholar
• Sato N, Ohta T, Kitagawa H, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004;24(3):679–685.
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581–589.
   PubMed Web of Science ®Google Scholar
• Liu H, Hu Q, D’Ercole AJ, et al. Histone deacetylase 11 regulates oligodendrocyte-specific gene expression and cell development in OL-1 oligodendroglia cells. Glia. 2009;57(1):1–12.
   PubMed Web of Science ®Google Scholar
• Villagra A, Cheng F, Wang HW, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009;10(1):92–100.
   PubMed Web of Science ®Google Scholar
• Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer. 2011;2(6):648–662.
   PubMedGoogle Scholar
• Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–5504.
   PubMed Web of Science ®Google Scholar
• Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res. 2015;38(6):933–949.
   PubMed Web of Science ®Google Scholar
• Lopez AT, Bates S, Geskin L. Current status of HDAC inhibitors in cutaneous T-cell lymphoma. Am J Clin Dermatol. 2018;19(6):805–819.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009;27(32):5410–5417.
   PubMed Web of Science ®Google Scholar
• Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol. 2015;170(1):96–109.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(29):4485–4491.
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol. 2007;25(21):3109–3115.
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015;168(6):811–819.
   PubMed Web of Science ®Google Scholar
• Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer. 2013;49(2):386–394.
   PubMed Web of Science ®Google Scholar
• Walewski J, Paszkiewicz-Kozik E, Borsaru G, et al. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study. Leuk Lymphoma. 2019;60(3):675–684.
   PubMed Web of Science ®Google Scholar
• Oka T, Miyagaki T. Novel and future therapeutic drugs for advanced mycosis fungoides and Sézary syndrome. Front Med. 2019;6:116.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder C, Han JJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328–335.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ,g inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–898.
   PubMed Web of Science ®Google Scholar
• Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med. 2003;81(4):235–245.
   PubMed Web of Science ®Google Scholar
• Izban KF, Ergin M, Qin JZ, et al. Constitutive expression of NF-κB is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol. 2000;31(12):1482–1490.
   PubMed Web of Science ®Google Scholar
• Ri M, Iida S, Ishida T, et al. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Sci. 2009;100(2):341–348.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Toni M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–4297.
   PubMed Web of Science ®Google Scholar
• Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159(1):105–112.
   PubMed Web of Science ®Google Scholar
• Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, et al. Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. Blood. 2019;134(13):1072–1083.
   PubMed Web of Science ®Google Scholar